GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BrainsWay Ltd (OTCPK:BRSYF) » Definitions » Price-to-Free-Cash-Flow

BrainsWay (BrainsWay) Price-to-Free-Cash-Flow : 16.92 (As of May. 23, 2024)


View and export this data going back to 2012. Start your Free Trial

What is BrainsWay Price-to-Free-Cash-Flow?

As of today (2024-05-23), BrainsWay's share price is $2.47. BrainsWay's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.15. Hence, BrainsWay's Price-to-Free-Cash-Flow Ratio for today is 16.92.

The historical rank and industry rank for BrainsWay's Price-to-Free-Cash-Flow or its related term are showing as below:

BRSYF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 17.8   Med: 18.75   Max: 20.15
Current: 18.29

During the past 11 years, BrainsWay's highest Price-to-Free-Cash-Flow Ratio was 20.15. The lowest was 17.80. And the median was 18.75.

BRSYF's Price-to-Free-Cash-Flow is ranked better than
72.97% of 333 companies
in the Medical Devices & Instruments industry
Industry Median: 34.18 vs BRSYF: 18.29

BrainsWay's Free Cash Flow per Share for the three months ended in Mar. 2024 was $0.07. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.15.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 42.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 34.40% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 17.60% per year.

During the past 11 years, BrainsWay's highest 3-Year average Free Cash Flow per Share Growth Rate was 49.90% per year. The lowest was -38.50% per year. And the median was 16.75% per year.


BrainsWay Price-to-Free-Cash-Flow Historical Data

The historical data trend for BrainsWay's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrainsWay Price-to-Free-Cash-Flow Chart

BrainsWay Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BrainsWay Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 19.31

Competitive Comparison of BrainsWay's Price-to-Free-Cash-Flow

For the Medical Devices subindustry, BrainsWay's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BrainsWay's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BrainsWay's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BrainsWay's Price-to-Free-Cash-Flow falls into.



BrainsWay Price-to-Free-Cash-Flow Calculation

BrainsWay's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.47/0.146
=16.92

BrainsWay's Share Price of today is $2.47.
BrainsWay's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.15.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

BrainsWay  (OTCPK:BRSYF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


BrainsWay Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BrainsWay's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


BrainsWay (BrainsWay) Business Description

Traded in Other Exchanges
Address
19 Hartum Street, 3rd Floor, Bynet Building, Har Hotzvim, Jerusalem, ISR, 9777518
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.